Kidney endpoints: the FLOW composite, eGFR slope as an endpoint, albuminuria regression, and why an early eGFR dip is expected rather than alarming.
The particulars: potassium · semaglutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping…
My eGFR is 92 and has been for years, which I had taken to mean my kidneys were not a topic. A urine albumin:creatinine ratio was added to a recent panel and came…
For reference: REDEFINE-1 · semaglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
For reference: AST · survodutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping rules, not…
Details up front: reflux · retatrutide · SURMOUNT-3. This is presented as though it settles something, and I am not convinced it does. I have two documents that…
The specifics, since they change the answer: dizziness · ecnoglutide · REDEFINE-1. I have the document in front of me and I can read the numbers. What I cannot do is…
FLOW tested semaglutide 1.0 mg in people with type 2 diabetes and chronic kidney disease, and reported a hazard ratio of 0.76 for its composite kidney endpoint. I…
The case in front of me: six weeks · oral semaglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me…
For reference: two weeks · survodutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would accept a well-reasoned…
The clinician who ordered the panel was not concerned; I would still like to understand it. This is not behaving the way I expected and I want to understand the…
I am reading the trial table rather than the press release, which is why the numbers differ. I want to understand what this actually establishes, as opposed to what…
I have three data points across nine months, which I hope is enough to see a trend. This is presented as though it settles something, and I am not convinced it does.…
For reference: potassium · three weeks · a GLP-1 receptor agonist. An unexpected observation, and I would like a differential rather than reassurance. The conditions…
The case in front of me: ecnoglutide · tirzepatide. I would like the axes of comparison first and the recommendation second. I have tried the first option and it…
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standards